sm1 71 Search Results


sm1 71  (MedChemExpress)
93
MedChemExpress sm1 71
a Study design of in vitro and in vivo experiments. b Western blot analysis of phosphorylated and total Mek1 and Erk in Trp53 −/− –ATII organoids. NC negative control group, WT group overexpressing WT MAP2K1 , MT group overexpressing MAP2K1 ΔE102−I103 . c Morphological changes (top), H&E staining (second row), and IHC of EpCAM (third row) and TTF-1 (bottom) in Trp53 −/− –ATII organoids after 5 days of culture. Scale bar, 50 µm. d Relative viability of organoids on days 1, 3, and 5. n = 3 biological replicates. e Relative organoid area of organoids on day 5. f – h Growth curve ( f ), end point illustration ( g , scale bar, 1 cm), and tumor weight ( h ) of Trp53 −/− ( n = 4), Trp53 −/− ; MAP2K1 WT ( n = 4), and Trp53 −/− ; MAP2K1 MT ( n = 4) allografts. i H&E staining and IHC of TTF-1, KRT7, and EpCAM of the Trp53 −/− ; MAP2K1 MT organoid allograft at the experiment endpoint (day 48). Scale bar, 50 µm. j Efficacy of <t>SM1-71,</t> an inhibitor of MAP2K1, in treating MAP2K1 MT , MAP2K1 WT , and negative-control Ba/F3 cells. * p < 0.05, ** p < 0.01, *** p < 0.001.
Sm1 71, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sm1+71/SM1-71/pmc12689645-402-0-1
Average 93 stars, based on 1 article reviews
sm1 71 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
sm1-71  (MuseChem Chemicals)
N/A
SM1-71 is a small-molecule inhibitor designed to target specific signaling pathways involved in disease processes, particularly in cancer and inflammatory diseases. While detailed information on SM1-71 may be limited, compounds of this nature are typically
   Buy from Supplier
sm1-71  (Biosynth Carbosynth)
N/A
   Buy from Supplier
sm1-71  (Aladdin Scientific Corporation)
N/A
SM1-71 (compound 5) is a potent TAK1 inhibitor, with a K i of 160 nM, it also can covalently inhibit MKNK2 , MAP2K1/2/3/4/6/7 , GAK , AAK1 , BMP2K , MAP3K7 , MAPKAPK5 , GSK3A/B
   Buy from Supplier
sm1-71  (TargetMol)
N/A
   Buy from Supplier
sm1-71-r  (Biosynth Carbosynth)
N/A
   Buy from Supplier

Image Search Results


a Study design of in vitro and in vivo experiments. b Western blot analysis of phosphorylated and total Mek1 and Erk in Trp53 −/− –ATII organoids. NC negative control group, WT group overexpressing WT MAP2K1 , MT group overexpressing MAP2K1 ΔE102−I103 . c Morphological changes (top), H&E staining (second row), and IHC of EpCAM (third row) and TTF-1 (bottom) in Trp53 −/− –ATII organoids after 5 days of culture. Scale bar, 50 µm. d Relative viability of organoids on days 1, 3, and 5. n = 3 biological replicates. e Relative organoid area of organoids on day 5. f – h Growth curve ( f ), end point illustration ( g , scale bar, 1 cm), and tumor weight ( h ) of Trp53 −/− ( n = 4), Trp53 −/− ; MAP2K1 WT ( n = 4), and Trp53 −/− ; MAP2K1 MT ( n = 4) allografts. i H&E staining and IHC of TTF-1, KRT7, and EpCAM of the Trp53 −/− ; MAP2K1 MT organoid allograft at the experiment endpoint (day 48). Scale bar, 50 µm. j Efficacy of SM1-71, an inhibitor of MAP2K1, in treating MAP2K1 MT , MAP2K1 WT , and negative-control Ba/F3 cells. * p < 0.05, ** p < 0.01, *** p < 0.001.

Journal: Cell Research

Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma

doi: 10.1038/s41422-025-01200-w

Figure Lengend Snippet: a Study design of in vitro and in vivo experiments. b Western blot analysis of phosphorylated and total Mek1 and Erk in Trp53 −/− –ATII organoids. NC negative control group, WT group overexpressing WT MAP2K1 , MT group overexpressing MAP2K1 ΔE102−I103 . c Morphological changes (top), H&E staining (second row), and IHC of EpCAM (third row) and TTF-1 (bottom) in Trp53 −/− –ATII organoids after 5 days of culture. Scale bar, 50 µm. d Relative viability of organoids on days 1, 3, and 5. n = 3 biological replicates. e Relative organoid area of organoids on day 5. f – h Growth curve ( f ), end point illustration ( g , scale bar, 1 cm), and tumor weight ( h ) of Trp53 −/− ( n = 4), Trp53 −/− ; MAP2K1 WT ( n = 4), and Trp53 −/− ; MAP2K1 MT ( n = 4) allografts. i H&E staining and IHC of TTF-1, KRT7, and EpCAM of the Trp53 −/− ; MAP2K1 MT organoid allograft at the experiment endpoint (day 48). Scale bar, 50 µm. j Efficacy of SM1-71, an inhibitor of MAP2K1, in treating MAP2K1 MT , MAP2K1 WT , and negative-control Ba/F3 cells. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: SM1-71 (MCE, Cat# HY-136848) was used as a MAP2K1 inhibitor.

Techniques: In Vitro, In Vivo, Western Blot, Negative Control, Staining